bioRxivImmunology
SARS-CoV-2 mechanistic correlates of protection: insight from modelling response to vaccines
M. Alexandre, R. Marlin, M. Prague, C. Severin, N. Kahlaoui, S. Cardinaud, T. Naninck, B. Delache, M. Surenaud, M. Galhaut, N. Dereuddre-Bosquet, M. Cavarelli, P. Maisonnasse, M. Centlivre, C. Lacabaratz, A. Wiedemann, S. Zurawski, G. Zurawski, O. Schwartz, R. W. Sanders, R. Le Grand, Y. Levy, R. Thiebaut
Abstract
The definition of correlates of protection is critical for the development of next generation SARS-CoV-2 vaccine platforms. Here, we propose a new framework for identifying mechanistic correlates of protection based on mathematical modelling of viral dynamics and data mining of immunological markers. The application to three different studies in non-human primates evaluating SARS-CoV-2 vaccines based on CD40-targeting, two-component spike nanoparticle and mRNA 1273 identifies and quantifies two main mechanisms that are a decrease of rate of cell infection and an increase in clearance of infected cells. Inhibition of RBD binding to ACE2 appears to be a robust mechanistic correlate of protection across the three vaccine platforms although not capturing the whole biological vaccine effect. The model shows that RBD/ACE2 binding inhibition represents a strong mechanism of protection which required significant reduction in blocking potency to effectively compromise the control of viral replication. One Sentence SummaryA framework for modelling the immune control of viral dynamics is applied to quantify the effect of several SARS-CoV-2 vaccine platforms and to define mechanistic correlates of protection.
- organism: non-human primate
- research focus: host-pathogen & immune response
- approach: statistical model
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Joint mechanistic modeling of viral and antibody responses to vaccines in non-human primates to quantify SARS-CoV-2 mechanistic correlates of protection
Marie Alexandre, Romain Marlin, … Mélanie Prague·bioRxiv·Jan 16, 2026
- Immune Correlates of Protection by mRNA-1273 Immunization against SARS-CoV-2 Infection in Nonhuman Primates
K. S. Corbett, M. C. Nason, … Leung·bioRxiv·Apr 20, 2021
- Adaptive immune determinants of viral clearance and protection in mouse models of SARS-CoV-2
B. Israelow, T. Mao, … A. Iwasaki·bioRxiv·May 19, 2021
- Intranasal SARS-CoV-2 RBD decorated nanoparticle vaccine enhances viral clearance in the Syrian hamster model
D. R. Patel, A. M. Minns, … T. C. Sutton·bioRxiv·Oct 27, 2022
- A recombinant receptor-binding domain in trimeric form generates completely protective immunity against SARS-CoV-2 infection in nonhuman primates
- BNT162b vaccines are immunogenic and protect non-human primates against SARS-CoV-2
A. B. Vogel, I. Kanevsky, … M. R Gutman·bioRxiv·Dec 11, 2020